Haemonetics Corporation (NYSE:HAE) – Equities researchers at Jefferies Group lifted their Q3 2018 EPS estimates for Haemonetics Corporation in a report released on Tuesday. Jefferies Group analyst A. Petrone now anticipates that the medical instruments supplier will post earnings of $0.46 per share for the quarter, up from their prior estimate of $0.45. Jefferies Group currently has a “Buy” rating and a $48.00 target price on the stock. Jefferies Group also issued estimates for Haemonetics Corporation’s Q4 2018 earnings at $0.43 EPS, FY2018 earnings at $1.70 EPS, FY2019 earnings at $1.95 EPS, FY2020 earnings at $2.39 EPS, FY2021 earnings at $3.00 EPS and FY2022 earnings at $3.50 EPS.
Several other equities research analysts have also commented on HAE. Morgan Stanley upped their price objective on Haemonetics Corporation from $43.00 to $51.00 and gave the stock an “equal weight” rating in a research report on Thursday. Barrington Research increased their target price on Haemonetics Corporation from $48.00 to $57.00 and gave the company an “outperform” rating in a research report on Wednesday. Craig Hallum reiterated a “hold” rating and set a $50.00 target price (up previously from $40.00) on shares of Haemonetics Corporation in a research report on Wednesday. TheStreet upgraded Haemonetics Corporation from a “c” rating to a “b-” rating in a research report on Monday, August 7th. Finally, BidaskClub upgraded Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. Haemonetics Corporation has a consensus rating of “Hold” and an average price target of $51.33.
TRADEMARK VIOLATION WARNING: “Q3 2018 Earnings Estimate for Haemonetics Corporation (HAE) Issued By Jefferies Group” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/11/12/q3-2018-earnings-estimate-for-haemonetics-corporation-hae-issued-by-jefferies-group.html.
Shares of Haemonetics Corporation (NYSE:HAE) opened at $54.52 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.17 and a quick ratio of 1.72. Haemonetics Corporation has a 52-week low of $36.44 and a 52-week high of $55.10. The company has a market capitalization of $2,879.64, a P/E ratio of 33.45, a price-to-earnings-growth ratio of 4.08 and a beta of 0.91.
Haemonetics Corporation (NYSE:HAE) last released its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.07. Haemonetics Corporation had a return on equity of 11.16% and a net margin of 0.50%. The business had revenue of $225.40 million for the quarter, compared to analyst estimates of $219.12 million. During the same quarter in the prior year, the firm posted $0.38 EPS. The business’s quarterly revenue was up 2.3% compared to the same quarter last year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Arizona State Retirement System raised its stake in Haemonetics Corporation by 1.1% in the 2nd quarter. Arizona State Retirement System now owns 27,397 shares of the medical instruments supplier’s stock valued at $1,082,000 after purchasing an additional 300 shares during the last quarter. BlackRock Inc. increased its stake in shares of Haemonetics Corporation by 48,854.9% in the 1st quarter. BlackRock Inc. now owns 6,289,728 shares of the medical instruments supplier’s stock worth $255,175,000 after acquiring an additional 6,276,880 shares during the last quarter. Aperio Group LLC increased its stake in shares of Haemonetics Corporation by 15.0% in the 2nd quarter. Aperio Group LLC now owns 10,695 shares of the medical instruments supplier’s stock worth $422,000 after acquiring an additional 1,393 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Haemonetics Corporation by 12.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 23,503 shares of the medical instruments supplier’s stock worth $928,000 after acquiring an additional 2,553 shares during the last quarter. Finally, Kirr Marbach & Co. LLC IN increased its stake in shares of Haemonetics Corporation by 56.3% in the 2nd quarter. Kirr Marbach & Co. LLC IN now owns 11,300 shares of the medical instruments supplier’s stock worth $446,000 after acquiring an additional 4,070 shares during the last quarter.
Haemonetics Corporation Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.